{
    "clinical_study": {
        "@rank": "26639", 
        "arm_group": [
            {
                "arm_group_label": "Tramadol hydrochloride/Acetaminophen Tab.", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Tramadol hydrochloride/Acetaminophen SR Tab.", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate effectness of Tramadol Hydrochloride/Acetaminophen\n      SR Tab. and Tramadol Hydrochloride/Acetaminophen Tab. in patients with low back pain."
        }, 
        "brief_title": "Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Low Back Pain", 
        "condition_browse": {
            "mesh_term": [
                "Back Pain", 
                "Low Back Pain"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult males/Females aged over 20 years\n\n          2. Patient with low back pain who needs analgesic administration\n\n          3. Patient with low back pain Who correspond with Class 1, 2 in Quebec Task Force\n             Classification\n\n          4. Pain VAS Value over 40 mm\n\n          5. Subjects who voluntarily or legal guardian agreed with written consent\n\n        Exclusion Criteria:\n\n          1. Patients with severe GI tract disorder, liver disease, renal disease, heart disease,\n             hypertension\n\n          2. Patients with obvious secondary cause(metastatic cancer, fracture, infectious\n             disease)\n\n          3. Patients who had taken back surgery within 24 weeks from the screening point\n\n          4. Patients who had taken opioid drug, psychotropic drug within 4 weeks from the\n             screening point\n\n          5. Patients who had taken steroid drug(oral, injection) within 4 weeks from the\n             screening point"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776515", 
            "org_study_id": "DW 0919 301 Version 1.00"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tramadol hydrochloride/Acetaminophen Tab.", 
                "intervention_name": "Tramadol hydrochloride/Acetaminophen Tab.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tramadol hydrochloride/Acetaminophen SR Tab.", 
                "intervention_name": "Tramadol hydrochloride/Acetaminophen SR Tab.", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Tramadol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Low back pain", 
            "Wontran", 
            "Wontran SR Tab.", 
            "Tramadol Hydrochloride/Acetaminophen"
        ], 
        "lastchanged_date": "January 23, 2013", 
        "official_title": "A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes in '100 mm pain VAS' value from baseline", 
            "time_frame": "0, 1, 7, 14, 28 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}